₹188.6*
MRP ₹209.5
10% off
₹178.07*
MRP ₹209.5
15% CB
₹31.43 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Prescription drugWhats That
Composition :
CLINDAMYCIN-1%W/V
Manufacturer/Marketer :
Torrent Pharmaceuticals Ltd
Consume Type :
TOPICAL
Return Policy :
Not Returnable
Expires on or after :
Drug-Drug Interactions
No Drug - Drug interactions found in our data. We may lack specific data on this medicine and are actively working to update our database. Consult your doctor for personalized advice
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Product Substitutes
Author Details
Drug-Diseases Interactions
CLINDAMYCIN-1%W/VOther bacterial intestinal infections
Severe
CLINDAMYCIN-1%W/VDisorders related to short gestation and low birth weight, not elsewhere classified
Severe
Drug-Diseases Interactions
Login/Sign Up
CLINDAMYCIN-1%W/VOther bacterial intestinal infections
Severe
How does the disease interact with Clinmiskin Solution 30 ml:
Almost all antibacterial medications have been associated with reports of Clostridioides difficile-associated diarrhoea (CDAD), formerly known as pseudomembranous colitis. It can vary from mild diarrhoea to deadly colitis.
How to manage the interaction:
Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhoea to colitis has been reported during treatment with antibacterial agents. Therapy should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis and pseudomembranous colitis. Appropriate fluid and electrolyte management, protein supplementation, and antibacterial treatment of C difficile is advised.
Almost all antibacterial medications have been associated with reports of Clostridioides difficile-associated diarrhoea (CDAD), formerly known as pseudomembranous colitis. It can vary from mild diarrhoea to deadly colitis.
How to manage the interaction:
Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhoea to colitis has been reported during treatment with antibacterial agents. Therapy should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis and pseudomembranous colitis. Appropriate fluid and electrolyte management, protein supplementation, and antibacterial treatment of C difficile is advised.
CLINDAMYCIN-1%W/VDisorders related to short gestation and low birth weight, not elsewhere classified
Severe
How does the disease interact with Clinmiskin Solution 30 ml:
Benzyl alcohol is frequently used as a preservative in the formulation of multidose vials for parenteral medicines. Manufacturers of pharmaceuticals believe that using them in neonates, especially preterm and underweight newborns, is contraindicated. In low birth weight preterm newborns, the use of benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been linked to mortality and serious respiratory and metabolic problems.
How to manage the interaction:
Parenteral medications containing benzyl alcohol as a preservative are contraindicated in neonates, particularly premature infants and infants of low birth weight.
Benzyl alcohol is frequently used as a preservative in the formulation of multidose vials for parenteral medicines. Manufacturers of pharmaceuticals believe that using them in neonates, especially preterm and underweight newborns, is contraindicated. In low birth weight preterm newborns, the use of benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been linked to mortality and serious respiratory and metabolic problems.
How to manage the interaction:
Parenteral medications containing benzyl alcohol as a preservative are contraindicated in neonates, particularly premature infants and infants of low birth weight.
CLINDAMYCIN-1%W/VOther diseases of liver
Moderate
How does the disease interact with Clinmiskin Solution 30 ml:
The liver is the primary site of Clinmiskin Solution 30 ml metabolism. Patients with significantly impaired hepatic function may have a rise in the blood concentration of Clinmiskin Solution 30 ml and a prolongation of the half-life. Additionally, the drug's usage may result in abnormal liver enzyme levels and jaundice. Patients with liver problems should receive Clinmiskin Solution 30 ml therapy with caution. When given every 8 hours, dosage modifications might not be required. However, with high-dose therapy, serum concentrations should be observed, and during prolonged therapy, regular liver function tests should be carried out.
How to manage the interaction:
Clinmiskin Solution 30 ml is primarily metabolized by the liver. Therapy with Clinmiskin Solution 30 ml should be administered cautiously in patients with liver disease. Serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.
The liver is the primary site of Clinmiskin Solution 30 ml metabolism. Patients with significantly impaired hepatic function may have a rise in the blood concentration of Clinmiskin Solution 30 ml and a prolongation of the half-life. Additionally, the drug's usage may result in abnormal liver enzyme levels and jaundice. Patients with liver problems should receive Clinmiskin Solution 30 ml therapy with caution. When given every 8 hours, dosage modifications might not be required. However, with high-dose therapy, serum concentrations should be observed, and during prolonged therapy, regular liver function tests should be carried out.
How to manage the interaction:
Clinmiskin Solution 30 ml is primarily metabolized by the liver. Therapy with Clinmiskin Solution 30 ml should be administered cautiously in patients with liver disease. Serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.
CLINDAMYCIN-1%W/VOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Clinmiskin Solution 30 ml:
Clinmiskin Solution 30 ml is partially removed by the kidney. Clinmiskin Solution 30 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Clinmiskin Solution 30 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Clinmiskin Solution 30 ml should be administered cautiously in patients with severely impaired renal function. Serum Clinmiskin Solution 30 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Clinmiskin Solution 30 ml is partially removed by the kidney. Clinmiskin Solution 30 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Clinmiskin Solution 30 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Clinmiskin Solution 30 ml should be administered cautiously in patients with severely impaired renal function. Serum Clinmiskin Solution 30 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
CLINDAMYCIN-1%W/VOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Clinmiskin Solution 30 ml:
Clinmiskin Solution 30 ml is partially removed by the kidney. Clinmiskin Solution 30 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Clinmiskin Solution 30 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Clinmiskin Solution 30 ml should be administered cautiously in patients with severely impaired renal function. Serum Clinmiskin Solution 30 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Clinmiskin Solution 30 ml is partially removed by the kidney. Clinmiskin Solution 30 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Clinmiskin Solution 30 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Clinmiskin Solution 30 ml should be administered cautiously in patients with severely impaired renal function. Serum Clinmiskin Solution 30 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Have a query?
